BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant

An analysis of mortality among more than 114,000 SARS-CoV-2–infected people in Scotland revealed that vaccine effectiveness against death caused by the delta variant 14 days or more after the second dose was 90% for the BNT162b2 vaccine and 91% for the ChAdOx1 nCoV-19 vaccine.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 385; no. 23; pp. 2195 - 2197
Main Authors Sheikh, Aziz, Robertson, Chris, Taylor, Bob
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 02.12.2021
Subjects
Adolescent
Adult
Age groups
BNT162 Vaccine
ChAdOx1 nCoV-19
Cohort Studies
Coronavirus
Coronaviruses
Correspondence
COVID-19 - genetics
COVID-19 - mortality
COVID-19 - prevention & control
COVID-19 vaccines
Effectiveness
Electron Transport Complex IV
Female
Genes
Humans
Immunization
Infections
Infectious Disease
Male
Medical research
Middle Aged
SARS-CoV-2
Scotland - epidemiology
Severe acute respiratory syndrome coronavirus 2
Socioeconomic factors
Surveillance
Vaccine Efficacy
Vaccines
Scotland
United Kingdom > UK
Online AccessGet full text
ISSN0028-4793
1533-4406
1533-4406
DOI10.1056/NEJMc2113864

Cover

More Information
Summary:An analysis of mortality among more than 114,000 SARS-CoV-2–infected people in Scotland revealed that vaccine effectiveness against death caused by the delta variant 14 days or more after the second dose was 90% for the BNT162b2 vaccine and 91% for the ChAdOx1 nCoV-19 vaccine.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Article-2
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMc2113864